Viability of European cross-border access opportunities to streamline access to ATMPs
In December 2021, the Regulation on Health Technology Assessment (HTA), as originally proposed by the European Commission, was adopted.[1] The Regulation...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Walter Colasante is a vice president in the Life Sciences Practice at CRA. He has experience in both the pharmaceutical and consulting industries. Walter has experience across a range of different therapeutic areas, most notably oncology, CNS, and rare diseases.
Prior to his role at CRA, Walter was a senior principal at a global life sciences company, consulting primarily in global market access strategies and EU parallel trade. In the pharmaceutical industry, he has held several clinical research positions. At a pharmaceutical corporation, he was International Brand Director for its retinal products franchise. He is fluent in Italian and French.